



# TCI EXPRESS

LEADER IN EXPRESS

Date: October 18, 2023

|   |   |
|---|---|
| <b>To,</b><br><b>The Listing Department,</b><br><b>The National Stock Exchange of India Ltd.,</b><br>“Exchange Plaza”,<br>Bandra Kurla Complex, Bandra (East),<br>Mumbai – 400051<br>Scrip Symbol: TCIEXP | <b>To,</b><br><b>The Listing Department,</b><br><b>BSE Ltd.,</b><br>Phiroz Jeejeebhoy Towers,<br>Dalal Street<br>Mumbai – 400001<br>Scrip Code:540212 |
|---|---|

**Sub: Newspaper Cuttings- Publication of Unaudited Financial Results for Q2/HY 2023-24**

Dear Sir/Madam,

We are forwarding herewith copies of newspaper cuttings of the above Financial Results, as published in the following newspapers:

| Name of Newspaper           | Date of Publishing |
|-----------------------------|--------------------|
| Financial Express (English) | October 18, 2023   |
| Nav Telangana (Telugu)      | October 18, 2023   |

This is for your information and necessary records please.

Thanking you,  
For **TCI Express Limited**

**PRIYANKA**  
**Company Secretary & Compliance Officer**  
Encl: as above

**TCI Express Limited**  
Website: [www.tciexpress.in](http://www.tciexpress.in)

**Corporate Office:** TCI House, Plot No. 69, Sector 32, Institutional Area, Gurugram - 122001, India  
**Tel.:** +91-124-2384090-94 • **Email:** [info@tciexpress.in](mailto:info@tciexpress.in) • **CIN:** L62200TG2008PLC061781  
**Registered Office:** Flat Nos. 306 & 307, 1-8-273, Third Floor, Ashoka Bhoopal Chambers,  
S. P. Road, Secunderabad – 500003 • **Tel.:** ++91 40 27840104

**TCI EXPRESS**

LEADER IN EXPRESS

**TCI EXPRESS LIMITED**  
CIN: L62200TG2008PLC061781  
Regd. Office : Flat Nos. 306 & 307, 1-8-271 to 273, Ashoka Bhoopal Chambers, S.P. Road, Secunderabad - 500 003, Telangana  
Corp. Office : TCI House, 69, Institutional Area, Sector-32, Gurugram-122 001, Haryana  
Tel.: + 91 124 2384090-94, E-mail: [secretarial@tcipress.in](mailto:secretarial@tcipress.in), Website: [www.tcipress.in](http://www.tcipress.in)

(Rs. in Crores except as stated otherwise)

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/ HALF YEAR ENDED SEPTEMBER 30, 2023**

| Sr. No | Particular   | Standalone    |               |                 |              |              |              | Consolidated  |              |                 |               |              |              |
|--------|--|---------------|---------------|-----------------|--------------|--------------|--------------|---------------|--------------|-----------------|---------------|--------------|--------------|
|        |  | Quarter Ended |               | Half Year Ended |              | Year Ended   |              | Quarter Ended |              | Half Year Ended |               | Year Ended   |              |
|        |  | Sep 30, 2023  | June 30, 2023 | Sep 30, 2022    | Sep 30, 2023 | Mar 31, 2023 | Sep 30, 2023 | June 30, 2023 | Sep 30, 2022 | Sep 30, 2023    | June 30, 2023 | Sep 30, 2022 | Mar 31, 2023 |
|        |  | Unaudited     | Unaudited     | Unaudited       | Unaudited    | Audited      | Unaudited    | Unaudited     | Unaudited    | Unaudited       | Unaudited     | Unaudited    | Audited      |
| 1      | Total Income from operations (net)   | 321.75        | 306.35        | 312.18          | 626.10       | 1,248.18     | 321.75       | 306.35        | 626.10       | 1,248.18        |               |              |              |
| 2      | Net Profit / (Loss) for the period (before Tax, Exceptional items and/or Extraordinary items)  | 47.15         | 42.87         | 49.91           | 90.02        | 184.53       | 47.15        | 42.87         | 90.02        | 184.53          |               |              |              |
| 3      | Net Profit / (Loss) for the period before Tax (after Exceptional items and/or Extraordinary items)   | 47.15         | 42.87         | 49.91           | 90.02        | 184.53       | 47.15        | 42.87         | 90.02        | 184.53          |               |              |              |
| 4      | Net Profit / (Loss) for the period after Tax (after Exceptional items and/or Extraordinary items)  | 35.58         | 32.33         | 37.79           | 67.91        | 139.28       | 35.58        | 32.33         | 67.91        | 139.28          |               |              |              |
| 5      | Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)) | 35.01         | 32.80         | 37.79           | 67.61        | 137.84       | 35.01        | 32.80         | 67.61        | 137.84          |               |              |              |
| 6      | Paid up Equity Share Capital (Face Value Rs. 2)  | 7.67          | 7.66          | 7.70            | 7.67         | 7.66         | 7.67         | 7.66          | 7.67         | 7.66            |               |              |              |
| 7      | Other Equity   | -             | -             | -               | -            | 588.71       | -            | -             | -            | -               |               | 588.71       |              |
| 8      | Earning per share - EPS (not annualized) - In Rs.  |               |               |                 |              |              |              |               |              |                 |               |              |              |
|        | Basic Earning Per Share  | 9.27          | 8.41          | 9.82            | 17.82        | 36.24        | 9.27         | 8.41          | 17.82        | 36.24           |               |              |              |
|        | Diluted Earning Per Share  | 9.26          | 8.40          | 9.80            | 17.59        | 36.20        | 9.26         | 8.40          | 17.59        | 36.20           |               |              |              |

**Notes:**

- The above is an extract of the detailed format of Quarter and Half Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Results are available on the Stock Exchange's websites at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on the Company's website ([www.tcipress.in](http://www.tcipress.in))
- The Financial Results for the Quarter and Half Year ended September 30, 2023 were reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on October 17, 2023. The Statutory Auditors of the Company have carried out the limited review of the same.
- The wholly owned subsidiary company was incorporated on February 14, 2023. Therefore, the figures for the quarter ended September 30, 2023 do not arise in the consolidated Financials.
- The Board has approved payment of interim dividend 150% (i.e. Rs 3.00 per equity share of face value of Rs 2/- per equity share) and October 26, 2023 shall be the record date for the purpose, decided in due consultation with Stock Exchanges.
- Previous period/year figures have been re-grouped or reclassified wherever applicable, to conform to current period's classification.

For TCI Express Limited

Place: Gurugram  
Date: October 17, 2023Chander Agarwal  
Managing Director**FRANKLIN TEMPLETON**

Franklin Templeton Mutual Fund  
One International Center, Tower 2, 12th and 13th Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai 400013

**Income Distribution cum capital withdrawal (IDCW) in Franklin India Debt Hybrid Fund, Franklin India Equity Savings Fund and Franklin India Dynamic Asset Allocation Fund of Funds**

The Trustees of Franklin Templeton Mutual Fund have decided to distribute the following Income Distribution cum capital withdrawal (IDCW):

| Name of the Schemes / Plans / Options                                 | Face Value per Unit (₹) | Amount of IDCW per Unit* (₹) | NAV per Unit as on October 16, 2023 (₹) |
|---|-------------------------|------------------------------|---|
| <b>Franklin India Debt Hybrid Fund (FIDHF)</b>                        |                         |                              |   |
| FIDHF - Monthly IDCW Plan   | 10.00                   | 0.085                        | 12.7354                                 |
| FIDHF - Monthly IDCW Plan - Direct                                    |                         | 0.095                        | 14.3315                                 |
| <b>Franklin India Equity Savings Fund (FIESF)</b>                     |                         |                              |   |
| FIESF - Monthly IDCW Plan   | 10.00                   | 0.030                        | 12.1189                                 |
| FIESF - Monthly IDCW Plan - Direct                                    |                         | 0.060                        | 12.7400                                 |
| <b>Franklin India Dynamic Asset Allocation Fund of Funds (FIDAAF)</b> |                         |                              |   |
| FIDAAF - IDCW Plan  | 10.00                   | 0.75                         | 40.3506                                 |
| FIDAAF - IDCW Plan - Direct   |                         | 0.90                         | 47.0692                                 |

The Record Date for the same will be October 20, 2023 (Friday). If in case the Record Date falls on a non-Business Day, the immediately following Business Day shall be the Record Date. All the Unitholders / Beneficial Owners of the IDCW plan / option of the scheme whose names appear in the records of Registrar / Depositories as on the Record Date shall be entitled to receive IDCW. The investors in the IDCW re-investment plan/option will be allotted units for the IDCW amount at the NAV of next Business Day after the Record Date.

# Please note that the IDCW payout shall be subject to the availability of distributable surplus and if the available distributable surplus as on the record date is lower than the aforementioned IDCW rate, then the available distributable surplus shall be paid out. The payout shall be subject to tax deducted at source i.e. TDS, as applicable.

**Pursuant to payment of IDCW, the NAV of the scheme would fall to the extent of payout and statutory levy (if applicable).**

For Franklin Templeton Asset Management (India) Pvt. Ltd.  
(Investment Manager of Franklin Templeton Mutual Fund)

Sd/-

Authorized Signatory

Date: October 17, 2023

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**KOTAK INFRASTRUCTURE DEBT FUND LIMITED**

CIN : U65910MH1988PLC048450

Regd. Office: 27BKC, C 27, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051  
Website: [kidf.kotak.com](http://kidf.kotak.com) Telephone: +91-22-61660000**Extract of unaudited financial results for the half year ended September 30, 2023**

Amount (₹ in Lakhs)

| Sr. No | Particulars   | Quarter ended September 30, 2023 (Unaudited) | Quarter ended September 30, 2022 (Unaudited) | Previous Year ended March 31, 2023 (Audited) |
|--------|---|--|--|--|
| 1      | Total Income from Operations  | 2,476.25                                     | 1,745.81                                     | 7,697.81                                     |
| 2      | Net Profit for the year (before Tax, Exceptional and Extraordinary items)   | 546.96                                       | 608.53                                       | 3,020.62                                     |
| 3      | Net Profit for the year before tax (after Exceptional and Extraordinary items)  | 546.96                                       | 608.53                                       | 3,020.62                                     |
| 4      | Net Profit for the year after tax (after Exceptional and Extraordinary items)   | 546.96                                       | 608.53                                       | 3,020.62                                     |
| 5      | Total Comprehensive Income for the year [Comprising Profit for the year (after tax) and Other Comprehensive Income (after tax)] | 547.16                                       | 611.40                                       | 3,021.99                                     |
| 6      | Paid up Equity Share Capital (Face Value ₹ 10 per share)  | 31,000.00                                    | 31,000.00                                    | 31,000.00                                    |
| 7      | Reserves (excluding Revaluation Reserve)  | 17,990.37                                    | 14,669.87                                    | 16,587.34                                    |
| 8      | Net Worth   | 48,990.37                                    | 45,669.87                                    | 47,587.34                                    |
| 9      | Paid up Debt Capital / Outstanding Debt   | 78,966.93                                    | 51,851.53                                    | 73,613.92                                    |
| 10     | Outstanding Redeemable Preference Shares (Nos. 14 each of ₹ 500000)   | -  | 72.63  | -  |
| 11     | Debt Equity Ratio   | 1.61   | 1.14   | 1.55   |
| 12     | Earnings per Share (of ₹ 10 each) - Basic & Diluted   | 0.18   | 0.20   | 0.97   |
| 13     | Capital Redemption Reserve  | 19.00  | 19.00  | 19.00  |
| 14     | Debt Redemption Reserve   | -  | -  | -  |

**Notes:**

- The above results were reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their respective meetings held on October 17, 2023.
- The above is an extract of the detailed format of quarterly financial results filed with BSE Limited under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the websites of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and the Company at [www.kidf.kotak.com](http://www.kidf.kotak.com)
- For the items referred in Regulation 52 (4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the BSE Limited and can be accessed on [www.bseindia.com](http://www.bseindia.com)
- Figures for the previous period/year have been regrouped wherever necessary to conform to current period/year presentation.
- These financial results have been prepared in accordance with the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 read with CIR/IMD/DF/169/2016 dated August 10, 2016.

Sd/-  
By order of the Board of DirectorsPlace : Mumbai  
Date : October 17, 2023

Kotak Infrastructure Debt Fund Limited

**"IMPORTANT"**

While care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

**FINANCIAL EXPRESS**

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.  
INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGES IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").  
**PUBLIC ANNOUNCEMENT**

**GPT HEALTHCARE LIMITED**

Our Company was originally incorporated as "Jibansatya Printing House Private Limited", a private limited company under the Companies Act, 1956 on August 17, 1989 at Kolkata, West Bengal. The name of our Company was subsequently changed to "GPT Healthcare Private Limited" so that the name of the Company is in consonance with the main objects of the Memorandum of Association in relation to the proposed business activities to be carried out by the Company. A fresh certificate of incorporation was issued by the Registrar of Companies, West Bengal at Kolkata ("RoC") on March 31, 2005. Thereafter pursuant to a special resolution passed by our Shareholders on September 3, 2021, our Company was converted to a public limited company and our name was changed to "GPT Healthcare Limited". A fresh certificate of incorporation consequent to change of name was issued by the RoC on September 15, 2021. For further details in relation to change in name and Registered and Corporate Office of our Company, see "History and Certain Corporate Matters" on page 216 of the draft red herring prospectus dated October 16, 2023, filed with Securities and Exchange Board of India on October 17, 2023 ("DRHP").

Registered and Corporate Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata - 700106, West Bengal; Tel: + (91) 33 4050 7000

Contact Person: Ankur Sharma, Company Secretary and Compliance Officer; Tel: + (91) 33 4050 7000; E-mail: [gpcsec@gptgroup.co.in](mailto:gpcsec@gptgroup.co.in); Website: [www.ils hospitals.com](http://www.ils hospitals.com); Corporate Identity Number: U70101WB1989PLC047402**OUR PROMOTERS: GPT SONS PRIVATE LIMITED, DWARIKA PRASAD TANTIA, DR. OM TANTIA AND SHREE GOPAL TANTIA**

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 400.00 MILLION BY OUR COMPANY (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 26,082,786 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY BANYANTREE GROWTH CAPITAL II, LLC (THE "INVESTOR SELLING SHAREHOLDER") (THE "OFFER FOR SALE"). THE OFFER WOULD CONSTITUTE [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY AND THE INVESTOR SELLING SHAREHOLDER IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER ("BRLM") AND WILL BE ADVERTISED IN ALL EDITIONS OF [●], AN ENGLISH NATIONAL DAILY NEWSPAPER WITH WIDE CIRCULATION, ALL EDITIONS OF [●], A HINDI NATIONAL DAILY NEWSPAPER WITH WIDE CIRCULATION AND KOLKATA EDITION OF [●], A BANGALI NEWSPAPER WITH WIDE CIRCULATION (BENGALI BEING THE REGIONAL LANGUAGE OF WEST BENGAL, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Investor Selling Shareholder may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLM and at the terminals of the Syndicate Member(s) and by intimation to the Designated Intermediaries and the Sponsor Banks, as applicable.

This is an Offer in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in terms of Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs" and such portion, the "QIB Portion"), provided that our Company and the Investor Selling Shareholder, in consultation with the BRLM, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"), out of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received from them at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders of which one-third portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-third portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 1.00 million, provided that unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders in accordance with the SEBI ICDR Regulations and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price all potential Bidders (except Anchor Investors) are mandatorily required to utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders using the UPI Mechanism, as applicable, pursuant to which their corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA Process. For further details, see "Offer Procedure" on page 454 of the DRHP.

This public announcement is made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares pursuant to the Offer and has filed the DRHP dated October 16, 2023 with the Securities and Exchange Board of India ("SEBI") on October 17, 2023.

Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made available to the public for comments, if any, for period of at least 21 days, from the date of filing by hosting it on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), on the websites of the Stock Exchanges i.e., BSE at [www.bseindia.com](http://www.bseindia.com) and NSE at [www.nseindia.com](http://www.nseindia.com) and on the website of the BRLM, i.e., JM Financial Limited at [www.jmfi.com](http://www.jmfi.com) and the website of our Company at [www.ils hospitals.com](http://www.ils hospitals.com). Our Company hereby invites the public to give comments on the DRHP dated October 16, 2023 filed with SEBI on October 17, 2023 with respect to disclosures made therein. The members of public are requested to send a copy of the comments sent to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by SEBI and/or our Company and/or the BRLM and/or the Company Secretary and Compliance Officer of our Company at their respective addresses mentioned herein below in relation to the Offer on or before 5:00 p.m. on the 21st day from the aforesaid date of filing the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the DRHP. Specific attention of the investors is invited to "Risk Factors" beginning on page 29 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the red herring prospectus ("Red Herring Prospectus") has been filed with the RoC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the DRHP.

The Equity Shares, when offered, through the Red Herring Prospectus, are proposed to be listed on the main board of the Stock Exchanges.

For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 223 of the DRHP.

The liability of the members of the Company is limited. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them see "Capital Structure" on page 87 of the DRHP.

| BOOK RUNNING LEAD MANAGER  | REGISTRAR TO THE OFFER   |
|--|--|
| <b>JM FINANCIAL</b><br>JM Financial Limited<br>7 <sup>th</sup> Floor, Energy Appasaheb Marathe Marg, Prabhadevi<br>Mumbai 400 025 Maharashtra, India<br>Tel: +91 22 6630 3030; E-mail: <a href="mailto:gpt.ipo@jmfi.com">gpt.ipo@jmfi.com</a> ; Website: <a href="http://www.jmfi.com">www.jmfi.com</a><br>Investor grievance E-mail: <a href="mailto:grievance_id@jmfi.com">grievance_id@jmfi.com</a><br>Contact person: Prachee Dhuri; SEBI registration number: INM00001036 | <b>LINK Intime</b><br>Link Intime India Private Limited<br>C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083<br>Tel: +91 22 810 811 4949; E-mail: <a href="mailto:gpt healthcare.ipo@linkintime.co.in">gpt healthcare.ipo@linkintime.co.in</a><br>Website: <a href="http://www.linkintime.co.in">www.linkintime.co.in</a><br>Investor grievance E-mail: <a href="mailto:gpt healthcare.ipo@linkintime.co.in">gpt healthcare.ipo@linkintime.co.in</a><br>Contact person: Shanti Gopalakrishnan; SEBI registration number: INR000004058 |

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For GPT HEALTHCARE LIMITED  
On behalf of the Board of Directors  
Sd/-  
Ankur Sharma  
Company Secretary and Compliance OfficerPlace: Kolkata, West Bengal  
Date: October 17, 2023

GPT HEALTHCARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DRHP dated October 16, 2023 with SEBI on October 17, 2023 and thereafter with the Stock Exchanges. The DRHP is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), on the websites of the Stock Exchanges i.e., BSE at [www.bseindia.com](http://www.bseindia.com) and NSE at [www.nseindia.com](http://www.nseindia.com) and on the website of the BRLM, i.e., JM Financial Limited at [www.jmfi.com](http://www.jmfi.com) and the website of our Company at [www.ils hospitals.com](http://www.ils hospitals.com). Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "Risk Factors" beginning on page 29 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

CONCEPT

**L&T TECHNOLOGY SERVICES LIMITED**

(A subsidiary of Larsen &amp; Toubro Limited)

Registered Office: L&T House, N.M. Marg, Ballard Estate, Mumbai - 400 001; Tel: (91 22) 6752 5656; Fax: (91 22) 6752 5893  
Email: [investor@lts.com](mailto:investor@lts.com), Website: [www.lts.com](http://www.lts.com), Corporate Identity Number: L72900MH2012PLC232169**EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2023**

| Particulars           | Consolidated            |                          |                          |                         |                          |                           | Standalone              |                          |                          |                         |                          |                           |
|-----------------------|-------------------------|--------------------------|--------------------------|-------------------------|--------------------------|---------------------------|-------------------------|--------------------------|--------------------------|-------------------------|--------------------------|---------------------------|
|                       | Quarter ended           |                          | Six months ended         |                         | Year ended               |                           | Quarter ended           |                          | Six months ended         |                         | Year ended               |                           |
|                       | Sep 30, 2023 (Reviewed) | June 30, 2023 (Reviewed) | Sep 30, 2022 (Reviewed)* | Sep 30, 2023 (Reviewed) | Sep 30, 2022 (Reviewed)* | March 31, 2023 (Audited)* | Sep 30, 2023 (Reviewed) | June 30, 2023 (Reviewed) | Sep 30, 2022 (Reviewed)* | Sep 30, 2023 (Reviewed) | Sep 30, 2022 (Reviewed)* | March 31, 2023 (Audited)* |
| Total Income          | 24,277                  | 23,491                   | 23,202                   | 47,768                  | 43,673                   | 90,188                    | 21,776                  | 20,917                   | 20,910                   | 42,693                  | 39,140                   | 81,110                    |
| Net profit before tax | 4,361                   | 4,311                    | 4,063                    | 8,672                   | 7,849                    | 16,860                    | 4,245                   | 4,143                    | 3,858                    | 8,388                   | 7,461                    | 15,999                    |
| Net profit after tax  | 3,159                   | 3,121                    | 3,006                    | 6,280                   | 5,768                    | 12,164                    | 3,082                   |                          |                          |                         |                          |                           |

